Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about NVS, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Inclisiran Sodium FDA approved Dec 2021 · Leqvio |
Percutaneous Coronary Intervention | Phase 4 · NCT06909565 | Recruiting |
| Iptacopan FDA approved Dec 2023 · Fabhalta |
Atypical Hemolytic Uremic Syndrome | Phase 3 · NCT05795140 | Recruiting |
| Remibrutinib FDA approved Sep 2025 · Rhapsido |
Relapsing Multiple Sclerosis | Phase 3 · NCT05156281 | Active not recruiting |
| Ribociclib FDA approved Mar 2017 · Kisqali |
Early Breast Cancer | Phase 3 · NCT05827081 | Active not recruiting |
| Asciminib FDA approved Oct 2021 · Scemblix |
Acute Lymphoblastic Leukemia | Phase 1/2 · NCT07387926 | Recruiting |
| Secukinumab FDA approved Jan 2015 · Cosentyx |
Psoriasis | N/A · NCT02786186 | Completed |
| Ansastrozole | Early Breast Cancer | Phase 3 · NCT05827081 | Active not recruiting |
| Therapeutic Corticosteroid | Primary Immune Thrombocytopenia (ITP) | Phase 3 · NCT05653349 | Active not recruiting |
| Leuprolide | Early Breast Cancer | Phase 3 · NCT05827081 | Active not recruiting |
| Pacibekitug | Myocardial Infarction | Phase 3 · NCT07938411 | Not yet recruiting |
| Pelabresib | Hematologic Malignancy | Phase 3 · NCT06401356 | Recruiting |
| Ianalumab (VAY736) | Primary Immune Thrombocytopenia (ITP) | Phase 3 · NCT05653349 | Active not recruiting |
| QMF149 | Asthma | Phase 3 · NCT05562466 | Recruiting |
| Fluorouracil | Metastatic Colorectal Cancer | Phase 2 · NCT04952753 | Terminated |
| Luxdegalutamide | Metastatic Hormone-sensitive Prostate Cancer | Phase 2 · NCT06991556 | Active not recruiting |
| Vincristine | Acute Lymphoblastic Leukemia | Phase 1/2 · NCT07387926 | Recruiting |
Also used in these trials (approved or third-party drugs, not NVS's own candidates): Budesonide, Letrozole, Goserelin, Ruxolitinib, Teriflunomide, Everolimus, Exemestane, Methotrexate, Hydrocortisone, Tislelizumab, Darolutamide, Bevacizumab.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
NVS holds $8.9B in cash and short-term investments and its operations are currently cash-flow neutral or positive.
Dilution pressure: 0 · Low
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when NVS files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| BlackRock, Inc. | Institution (13G, 5%+) | 145,227,650 | 7.61% | 2026-09-30 |
| NOVARTIS AG 10% owner |
Insider | 24,030,382 | 1.26% | 2025-10-28 |
| Fisher Asset Management, LLC | Institution (13F) | 16,762,528 | 0.88% | 2026-09-30 |
| Morgan Stanley | Institution (13F) | 8,437,223 | 0.44% | 2026-09-30 |
| Dimensional Fund Advisors LP | Institution (13F) | 7,875,541 | 0.41% | 2026-09-30 |
| Primecap Management Company | Institution (13F) | 6,585,464 | 0.35% | 2026-09-30 |
| LOOMIS SAYLES & CO L P | Institution (13F) | 4,834,120 | 0.25% | 2026-09-30 |
| Bank of America Corporation | Institution (13F) | 4,560,856 | 0.24% | 2026-09-30 |
| Goldman Sachs Group Inc | Institution (13F) | 3,296,470 | 0.17% | 2026-09-30 |
| JPMORGAN CHASE & CO | Institution (13F) | 2,548,730 | 0.13% | 2026-09-30 |
| Northern Trust Corporation | Institution (13F) | 2,532,827 | 0.13% | 2026-09-30 |
Share count 1,908,151,679 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the largest 13F holders (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for NVS and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →